Dr. Rami Komrokji, MD
Claim this profileMoffitt Cancer Center
Area of expertise
Myelodysplastic Syndrome
Rami Komrokji, MD has run 9 trials for Myelodysplastic Syndrome. Some of their research focus areas include:
Acute Myelogenous Leukemia
Rami Komrokji, MD has run 5 trials for Acute Myelogenous Leukemia.
Affiliated Hospitals
Moffitt Cancer Center
H. Lee Moffitt Cancer Center And Research Institute
Clinical Trials Rami Komrokji, MD is currently running
Venetoclax + CLAG-M
for AML
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Recruiting
1 award
Phase 2
6 criteria
Epoetin Alfa vs Luspatercept
for Myelodysplastic Syndrome
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
Recruiting
2 awards
Phase 3
More about Rami Komrokji, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Rami Komrokji, MD has experience with
- Luspatercept
- Venetoclax
- Epoetin Alfa
- Oral Azacitidine
- Placebo For Oral Azacitidine
- Quality Of Life Model
Breakdown of trials Rami Komrokji, MD has run
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Anemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rami Komrokji, MD specialize in?
Rami Komrokji, MD focuses on Myelodysplastic Syndrome and Acute Myelogenous Leukemia. In particular, much of their work with Myelodysplastic Syndrome has involved SF3B1 positive patients, or patients who are ZRSR2 positive.
Is Rami Komrokji, MD currently recruiting for clinical trials?
Yes, Rami Komrokji, MD is currently recruiting for 5 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Rami Komrokji, MD has studied deeply?
Yes, Rami Komrokji, MD has studied treatments such as Luspatercept, Venetoclax, Epoetin Alfa.
What is the best way to schedule an appointment with Rami Komrokji, MD?
Apply for one of the trials that Rami Komrokji, MD is conducting.
What is the office address of Rami Komrokji, MD?
The office of Rami Komrokji, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.